Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells (Q39434943)

11 September 2017

title

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells (English)

1 reference

11 September 2017

main subject

dasatinib monohydrate

1 reference

1 reference

1 reference

1 reference

Lori Rice

1

1 reference

11 September 2017

Sharon Lepler

series ordinal

2

1 reference

11 September 2017

Christina Pampo

series ordinal

3

1 reference

11 September 2017

Dietmar W Siemann

series ordinal

4

1 reference

11 September 2017

language of work or name

1 reference

1 December 2011

1 reference

Clinical & Experimental Metastasis

11 September 2017

published in

1 reference

11 September 2017

volume

29

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

133-142

1 reference

https://scigraph.springernature.com/pub.10.1007/s10585-011-9436-2

11 September 2017

exact match

0 references

cites work

Cancer metastasis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

New molecular targets in bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

SRC: A Century of Science Brought to the Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Docetaxel-based combination therapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeting the tumor microenvironment with SRC kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Src continues aging: current and future clinical directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Src kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10585-011-9436-2

Emerging treatment options for patients with castration-resistant prostate cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130962

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Regulation of SRC family kinases in human cancers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22130962

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10585-011-9436-2

1 reference

11 September 2017

1 reference